Cost-Effectiveness Analysis of Qsymia for Weight Loss

Finkelstein, Eric; Kruger, Eliza; Karnawat, Sunil
July 2015
PharmacoEconomics;Jul2015, Vol. 33 Issue 7, p699
Academic Journal
Background: Phase 3 clinical trial results reveal that Qsymia is a clinically effective long-term treatment for obesity, but whether this treatment is cost-effective compared to a diet and lifestyle intervention has yet to be explored. Objective: To quantify the incremental cost-effectiveness of Qsymia (phentermine and topiramate extended-release) for health-related quality of life improvements. Study design and methods: Estimates are based on cost and quality of life outcomes from a 56-week, multicenter, placebo-controlled, phase 3 clinical trial undertaken in 93 health centers in the US. Participants were overweight and obese adults (aged 18-70 years) with a body-mass index of 27-45 kg/m and two or more comorbidities (hypertension, dyslipidemia, diabetes or pre-diabetes or abdominal obesity). The intervention was diet and lifestyle advice plus the recommended dose of Qsymia (phentermine 7.5 mg plus topiramate 46.0 mg) vs. control, which included diet and lifestyle advice plus placebo. The study was from the payer perspective. Costs included the prescription cost, medication cost offsets and physician appointment costs. Effectiveness was measured in terms of quality-adjusted life years gained (QALYs). The main outcome measure was incremental cost per QALY gained of the intervention relative to control. Results: Our base-case model, in which participants take Qsymia for 1 year with benefits linearly decaying over the subsequent 2 years, generates an incremental cost-effectiveness ratio (ICER) of $48,340 per QALY gained. Using the base-case assumptions, probabilistic sensitivity analyses reveal that the ICER is below $50,000 per QALY in 54 % of simulations. However, results are highly dependent on the extent to which benefits are maintained post medication cessation. If benefits persist for only 1 year post cessation, the ICER increases to $74,480. Conclusion: Although base-case results suggest that Qsymia is cost-effective, this result hinges on the time on Qsymia and the extent to which benefits are maintained post medication cessation. This should be an area of future research.


Related Articles

  • Cost-effectiveness of a primary care intervention to treat obesity. Tsai, A G; Wadden, T A; Volger, S; Sarwer, D B; Vetter, M; Kumanyika, S; Berkowitz, R I; Diewald, L K; Perez, J; Lavenberg, J; Panigrahi, E R; Glick, H A // International Journal of Obesity;Aug2013 Supplement, Vol. 37, pS31 

    Background:Data on the cost-effectiveness of the behavioral treatment of obesity are not conclusive. The cost-effectiveness of treatment in primary care settings is particularly relevant.Methods:We conducted a within-trial cost-effectiveness analysis of a primary care-based obesity intervention....

  • THE NEW PRESCRIPTIONS.  // Marie Claire (US Edition);Oct2012, Vol. 19 Issue 10, p270 

    The article offers a preview on the two diet medications approved by the U.S. Food and Drug Administration (FDA), the Belviq and the combined phentermine and topiramate drug called Qsymia and another drug, the Contrave, which is to be reviewed by the agency after it was rejected in 2011.

  • Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Garvey, W. Timothy; Ryan, Donna H.; Look, Michelle; Gadde, Kishore M.; Allison, David B.; Peterson, Craig A.; Schwiers, Michael; Day, Wesley W.; Bowden, Charles H. // American Journal of Clinical Nutrition;Feb2012, Vol. 95 Issue 2, p297 

    Background: Obesity is a serious chronic disease. Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has previously shown significant weight loss compared with placebo in a 56-wk study in overweight and obese subjects with ≥2 weight-related...

  • GPs should join debate on potential risk versus reward of obesity drug. Castaneda, Reynald // New Zealand Doctor;10/8/2014, p14 

    The article focuses on the debate by general practitioners (GP) and clinicians in New Zealand on the risks and reward of the obesity drug phentermine.

  • Phentermine/Topiramate (Qsymia) for Chronic Weight Management. GAZEWOOD, JOHN D.; BARRY, KATHLEEN // American Family Physician;10/15/2014, Vol. 90 Issue 8, p576 

    The article presents a drug review on the mechanism of action and efficacy of phentermine/topiramate (Qsymia) for chronic weight management. Topics discussed include potential safety issues in using the drug such as nephrolithiasis, cardiac risk, and teratogenicity, common side effects of the...

  • Cost-Effectiveness of Surgically Induced Weight Loss for the Management of Type 2 Diabetes: Modeled Lifetime Analysis. Keating, Catherine L.; Dixon, John B.; Moodie, Marjory L.; Peeters, Anna; Bulfone, Liliana; Maglianno, Dianna J.; O'Brien, Paul E. // Diabetes Care;Apr2009, Vol. 32 Issue 4, p567 

    OBJECTIVE -- To estimate the cost-effectiveness of surgically induced weight loss relative to conventional therapy for the management of recently diagnosed type 2 diabetes in class HI obese patients. RESEARCH DESIGN AND METHODS--This study builds on a within-trial cost-efficacy analysis. The...

  • The value of the $50 000 per QALY threshold.  // PharmacoEconomics & Outcomes News;Sep2014, Vol. 711 Issue 1, p9 

    The article reflects on the value of the $50,000 per quality-adjusted life year (QALY) threshold in the U.S. for assessing the cost-effectiveness of an intervention.

  • Ranibizumab cost effective for common cause of vision loss.  // PharmacoEconomics & Outcomes News;11/24/2012, Issue 667, p9 

    The article discusses three studies on the cost effectiveness of ranizumab for macular oedema secondary to branch or central retinal vein occlusion (BRVO or CRVO) treatment when compared to laser photocoagulation therapy. The study in Great Britain shown that ranibizumab has incremental...

  • Ethical and Value Issues in Insurance Coverage for Cancer Treatment. Brock, Dan W. // Oncologist;Mar2010 Supplement, Vol. 15, p36 

    Many new cancer drugs provide only limited benefits, but at very great cost, for example, $200,000 -$300,000 per quality-adjusted life year produced. By most standards of value or cost-effectiveness, this does not represent good value. I first review several of the causes of this value failure,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics